Price T Rowe Associates Inc Alkermes Plc. Transaction History
Price T Rowe Associates Inc
- $883 Billion
- Q2 2025
A detailed history of Price T Rowe Associates Inc transactions in Alkermes Plc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 10,041,900 shares of ALKS stock, worth $275 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
10,041,900
Previous 11,788,245
14.81%
Holding current value
$275 Million
Previous $389 Million
26.19%
% of portfolio
0.03%
Previous 0.05%
Shares
19 transactions
Others Institutions Holding ALKS
# of Institutions
394Shares Held
176MCall Options Held
558KPut Options Held
427K-
Black Rock Inc. New York, NY29.1MShares$796 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.5MShares$506 Million0.01% of portfolio
-
State Street Corp Boston, MA8.21MShares$225 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.41MShares$175 Million1.86% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny5.81MShares$159 Million0.24% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.49B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...